PITTSBURGH (AP) -- Mylan Inc. said Monday it will start selling a generic version of Novartis AG's Vivelle-Dot estrogen patch in late 2013.
Mylan said it settled a patent lawsuit filed by Novartis Pharmaceuticals. Novartis will grant Mylan a license to start selling a generic version of Vivelle-Dot by Dec. 16, 2013. It said U.S. sales of the patch totaled $240 million over the 12 months ended Sept. 30.
Mylan asked the Food and Drug Administration to approve a generic version of the patch in March. The brand-name version is marketed by Novartis and Noven Pharmaceuticals Inc.
Shares of Mylan lost 21 cents to $17.65 in morning trading as the markets slumped. Novartis stock fell 71 cents to $39.33.